Giuseppe Turchetti

Mar 21, 2023 | mdpi.com | Valentina Lorenzoni |Rosa Gini |Giuseppe Turchetti |Irma Convertino

3. DiscussionThis descriptive exploration of baricitinib and tofacitinib utilization showed that these new drugs were used in accordance with labels [,] and clinical guideline recommendations []. In line with these, JAKi was used at least as a second-line treatment pharmacological approach when csDMARDs alone failed in controlling RA disease.